DY enters the back half of fiscal 2027 as one of the cleaner beat-and-raise stories in infrastructure services this quarter. The company reported Q1 FY2027 adjusted EPS of $4.42 against a $4.10 consensus, while revenue came in at $1.964 billion — nearly $300 million ahead of the $1.670 billion estimate. Management then raised full-year sales guidance to $7.38–$7.65 billion, a substantial step up from the prior $6.85–$7.15 billion range and well above the Street's $7.05 billion forecast. That combination — a blowout quarter followed by a guidance raise that itself beats estimates — is the kind of setup that breaks through the noise.
Short sellers have been quietly rebuilding positions into this result. Short interest climbed 28% over the past month to reach 6.1% of free float. The move accelerated from late April, when roughly 300,000 additional shares came onto loan over a four-week stretch. That said, the borrow market is far from stressed: availability is exceptionally loose at around 1,500% — meaning there are roughly fifteen shares available in the lending pool for every one currently shorted. Cost to borrow remains trivial at 0.45%, up around 4% on the week but well within the low range it has occupied all year. With that kind of supply overhang, the short-side rebuild reads more like measured skepticism than a conviction bet — and Wednesday's price reaction will have squeezed some of those recent additions.
The Street has been uniformly constructive. Every analyst change on record over the past three months carried a Buy or Overweight rating, with JP Morgan, B. Riley, Keybanc, and BofA all raising price targets in early March following the prior earnings print. The mean target heading into Wednesday stood at $473.82, with the stock trading around $420 — implying roughly 13% upside on pre-earnings consensus. That gap may narrow materially as firms update targets to reflect the raised guidance. Valuation is not cheap: the trailing P/E runs near 27x and EV/EBITDA around 14.4x, both ticking slightly higher this week. But with a forward EPS growth estimate that has been tracking sharply higher — the 12-month forward EPS growth factor ranked near the 50th percentile before today's print — the multiple may be easier for the Street to digest in light of the new guidance range. The ORTEX short score is a benign 45.9, sitting near the lower half of its range, which corroborates the view that short-side conviction remains limited.
The ownership picture adds useful texture. Peconic Partners, a specialist manager, holds over 13.7% of shares — an unusually concentrated anchor. BlackRock added around 155,000 shares through April, reaching 12.9%. The combination of a large specialist holder and passive accumulation from the index managers is a relatively stable base. Insider activity from late March showed the CEO and CFO selling at around $342 — well below the current price — following the routine award cycle, so those sales look more like tax-driven disposition than a signal on valuation.
The options market turned incrementally more cautious heading into results. The put/call ratio reached 0.54 by Tuesday, about 1.3 standard deviations above the 20-day mean of 0.45, reflecting above-average demand for downside protection into the print. The full-year 52-week range on PCR runs from 0.14 to 1.47, so current levels are far from extreme — but the drift higher since early May was clear. The acquisition of National Technology Integrators for approximately $280 million, announced alongside the earnings release, adds a new variable for the Street to model: it diversifies DY's capabilities but introduces integration risk that will likely feature in analyst Q&A.
The next focus shifts to post-earnings analyst revisions and updated price targets, and to how quickly the market absorbs the NTI acquisition rationale alongside the raised guidance.
See the live data behind this article on ORTEX.
Open DY on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
